In October 2015, the FDA approved liposomal irinotecan (Onivyde) in combination with 5-fluorouracil (5-FU)/leucovorin for the treatment of patients with metastatic pancreatic cancer following prior gemcitabine-based chemotherapy, according to findings from the pivotal phase 3 NAPOLI-1 trial. Read more . . .
Among limited options, moving effective therapies into earlier lines of treatment is an area of significant interest in metastatic pancreatic cancer, said Dae Won Kim, MD.